Magmedi 97 mg tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Magnesium

Available from:

Kora Corporation Limited trading as Kora Healthcare

ATC code:

A12CC04

INN (International Name):

Magnesium

Dosage:

97 milligram(s)

Pharmaceutical form:

Tablet

Therapeutic area:

magnesium citrate

Authorization status:

Marketed

Authorization date:

2021-03-26

Patient Information leaflet

1
PACKAGE LEAFLET: INFORMATION FOR THE USER
MAGMEDI 97 MG TABLETS
magnesium
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Magmedi is and what it is used for
2.
What you need to know before you take Magmedi
3.
How to take Magmedi
4.
Possible side effects
5.
How to store Magmedi
6.
Contents of the pack and other information
1.
WHAT MAGMEDI IS AND WHAT IT IS USED FOR
Magmedi contains the active ingredient magnesium citrate nonahydrate
equivalent to 97.2 mg (4
mmol) of magnesium.
Magmedi is intended for the treatment and prevention of magnesium
deficiency in adults,
adolescents and children aged from 12 years.
Magnesium is an essential mineral which is particularly important in
nerve and muscle function in
addition to other activities within the body.
You must talk to a doctor if you do not feel better or if you feel
worse after taking this medicine.
Magmedi is not intended for the treatment of either severe magnesium
loss (blood magnesium level
is less than 0.4mmol/L) or severe symptoms. Treatment with oral
magnesium can begin when blood
magnesium levels rise above 0.4mmol/L or when the severe symptoms are
no longer present.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE MAGMEDI
DO NOT TAKE MAGMEDI
•
if you are allergic to magnesium citrate nonahydrate or any of the
other ingredients of this
medicine (listed in section 6).
•
if you have severe kidney problems
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Magmedi:
•
if you suffer from kidney problems.
•
if you suf

Summary of Product characteristics

Health Products Regulatory Authority
15 February 2023
CRN00D9F0
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Magmedi 97 mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains magnesium citrate nonahydrate equivalent to 97.2
mg (4 mmol) of magnesium.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
White, oblong tablet, marked with "Mg" and "97" on either side of a
score line on one side. Dimensions: 18 mm x 8.7 mm. The
score line is only to facilitate breaking for ease of swallowing and
not to divide into equal doses.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Magmedi is indicated for the treatment and prevention of magnesium
deficiency in adults, adolescents and children aged from
12 years.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The duration of magnesium treatment required will depend on the
clinical circumstances of each patient
It is recommended that serum magnesium levels should be monitored at
regular intervals e.g. every 3-6 months, particularly in
children and in patients with renal impairment.
Posology
ADULTS (> 18 YEARS)
The recommended daily dose for an adult (> 18 years) is 12-24 mmol
magnesium, e.g. 1 – 2 tablets administered 3 times a day
(equivalent to 291.6– 583.2 mg magnesium or 12-24 mmol magnesium
daily).
CHILDREN AND ADOLESCENTS (12 TO 18 YEARS)
The recommended daily dose for children (12 to 18 years) and
adolescents is 12 mmol magnesium, e.g. 1 tablet administered 3
times a day (equivalent to 291.6 mg magnesium or 12 mmol magnesium
daily).
Special populations
CHILDREN LESS THAN 12 YEARS:
Magmedi is not recommended for children less than 12 years as
the safety and efficacy of Magmedi in children less than 12 years has
not yet been established.
Other pharmaceutical forms/strengths may be more appropriate for
administration to
this population.
ELDERLY:
As older patients may have diminished renal function, dose adjustments
may be required according to their renal function
status (see Renal impairmen